The 11 references in paper P. Isaev A., D. Semin Yu., P. Rumyantsev O., A. Il’in A., V. Pol’kin V., T. Agababyan A., S. Vasil’kov V., V. Medvedev S., N. Zhelonkina V., П. Исаев А., Д. Семин Ю., П. Румянцев О., А. Ильин А., В. Полькин В., Т. Агабабян А., С. Васильков В., В. Медведев С., Н. Желонкина В. (2016) “Клинический опыт применения препарата ленватиниб у пациентов с прогрессирующим дифференцированным раком щитовидной железы, рефрактерным к терапии радиоактивным йодом // Clinical experience in using lenvatinib in patients with progressive, radioactive iodine-refractory differentiated thyroid cancer” / spz:neicon:ogsh:y:2016:i:2:p:65-69

1
O’Neill C.J., Oucharek J., Learoyd D., Sidhu S.B. Standard and emerging therapies for metastatic differentiated thyroid cancer. Oncologist 2010;15(2):146–56.
(check this in PDF content)
2
Isaacs J.D., McMullen T.P., Sudhu S.B. et al. Predictive value of the Delphian and level VI nodes in papillary thyroid cancer. ANZ J Surg 2010;80(11):834–8.
(check this in PDF content)
3
Shimaoka K., Schoenfeld D.A., DeWys W.D. et al. A randomized trial of doxorubicin versus doxorubicin plus cisplatin in patients with advanced thyroid carcinoma. Cancer 1985;56(9):2155–60.
(check this in PDF content)
4
Brose M.S., Nutting C.M., Jarzab B. et al. Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trial. Lancet 2014;384(9940): 319–28.
(check this in PDF content)
5
Carr L.L., Mankoff D.A., Goulart B.H. et al. Phase II study of daily sunitinib in FDG-PET-positive, iodine-refractory differentiated thyroid cancer and metastatic medullary carcinoma of the thyroid with functional imaging correlation. Clin Cancer Res 2010;16(21):5260–8.
(check this in PDF content)
6
Bible K.C., Suman V.J., Molina J.R. et al. Efficacy of pazopanib in progressive, radioiodine-refractory, metastatic differentiated thyroid cancers: results of a phase 2 consortium study. Lancet Oncol 2010;11(10):962–72.
(check this in PDF content)
7
Locati L.D., Licitra L., Agate L. et al. Treatment of advanced thyroid cancer with axitinib: Phase 2 study with pharmacokinetic/ pharmacodynamic and quality-of-life assessments. Cancer 2014;120(17):2694–703.
(check this in PDF content)
8
Hoftijzer H., Heemstra K.A., Morreau H. et al. Beneficial effects of sorafenib on tumor progression, but not on radioiodine uptake, in patients with differentiated thyroid carcinoma. Eur J Endocrinol 2009;161(6):923–31.
(check this in PDF content)
9
Leboulleux S., Bastholt L., Krause T. et al. Vandetanib in locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 2 trial. Lancet Oncol 2012;13(9):897–905.
(check this in PDF content)
10
Инструкция по применению лекарственного препарата для медицинского применения Ленвима. Доступно по ссылке: http://www.rlsnet.ru/tn_index_id_87756.htm. [Instructions for use of medicinal product for medical use Lenvima. Available at: http://www. rlsnet.ru/tn_index_id_87756.htm. (In Russ.)].
(check this in PDF content)
11
Schlumberger M., Tahara M., Wirth L.J. et al. Lenvatinib versus placebo in radioiodine-refractory thyroid cancer. N Engl J Med 2015;372(7):621–30.
(check this in PDF content)